Long non-coding ribonucleic acid W5 inhibits progression and predicts favorable prognosis in hepatocellular carcinoma

Table 1 Association of long non-coding ribonucleic acid W5 expression with clinicopathologic features in hepatocellular carcinoma patients

Parameters	Group	Total	W5 expression		P value
			Low	High
Gender	Male	70	34	36	0.791
	Female	16	10	6
Age (yr)	≤ 60	30	15	15	0.579
	> 60	56	28	28
Tumor size (cm)	< 3 cm	21	6	15	0.007b
	≥ 3 cm	65	38	27
AFP	< 20	39	21	18	0.328
	≥ 20	47	22	25
Histological grade	Well/moderate-poor	52/34	5/28	47/6	0.046a
Clinical stage	I/II	50	23	27	0.501
Tumor number	III	36	20	16
	Solitary	76	36	40	0.312
	Multiple	10	7	3
Drinking status	Yes	42	24	18	0.276
	No	44	19	25
Smoking status	Yes	36	18	18	0.584
	No	50	24	26
PVTT	Yes	32	22	10	0.024a
	No	54	21	33
Microvascular invasion	Yes	70	36	34	0.568
	No	16	6	10
Liver cirrhosis	Absence	59	30	29	0.489
HBV	Yes	55	25	30	0.365
	No	31	18	13

^aP < 0.05.

^bP < 0.01. PVTT: Portal vein tumor thrombosis; HBV: Hepatitis B virus.

Table 2 Cox proportional hazards model analysis of clinicopathologic features related to overall survival in terms of long non-coding ribonucleic acid W5 expression in hepatocellular carcinoma patients

Variables	Univariate analysis			Multivariate analysis
	P value	HR	95%CI	P value	HR	95%CI
Expression (high/low)	0.041a	1.672	1.032-2.159	0.027a	1.285	0.867-2.155
Pathologic-Stage (I + II/III + IV)	0.001a	2.584	1.934-4.162	0.159	2.436	0.715-7.667
Pathologic-T (T1 + T2/T3 + T4)	0.004a	4.068	1.573-8.869	0.014a	10.638	2.314-57.649
Pathologic-M (M0/M1)	0.007a	5.294	3.195-7.657	0.005a	3.082	1.726-5.342
Pathologic-N (N0/N1 + N2 + N3)	0.002a	2.413	1.519-3.969	0.246	0.719	0.312-1.911
Age (< 60/ ≥ 60 yrs)	0.342	1.402	0.914-2.357
Gender (female/male)	0.258	1.324	0.849-1.905

^aP < 0.05. HR: Hazard ratio; CI: Confidence interval.